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ABSTRACT
Objectives: To conduct a cost-beneﬁt assessment of pre-
vention of sudden cardiac deaths with an implantable car-
dioverter deﬁbrillator (ICD) versus amiodarone from the
perspective of the health-care systems in the UK and France.
Methods: Course after implantation with an ICD or taking
amiodarone was modeled using discrete event simulation;
1000 pairs of identical patients were simulated 100 times for
each analysis. Rates of life-threatening arrhythmia and death
from other causes were assumed identical, but the case fatal-
ity of arrhythmia and hospitalization differ between treat-
ments. Rates were based on published data, primarily from
the Sudden Cardiac Death in Heart Failure Trial (SCD-
HeFT). Direct medical costs (in 2004 Euros) and lives saved
were estimated over 5 years. The monetary value of a life
(UK €2.1 million, France €2.0 million) was applied to this
beneﬁt and examined relative to the net investment required.
Results: ICDs decreased deaths during the 5 years from
37.0% to 29.7% at a net cost of €26,222 to €20,008 per
patient, yielding cost-beneﬁt ratios of 0.17 (UK) and 0.14
(France)—more than a 5 to 1 return on investment. Sensitiv-
ity analyses showed ICDs represent value for money when-
ever a life is valued at least at €274,000.
Conclusion: In these European countries where society val-
ues a life at more than €2 million, ICDs are a worthwhile
investment compared with amiodarone for primary preven-
tion of sudden cardiac deaths in patients with heart failure.
Keywords: cost-beneﬁt analysis, ICD, implantable cardio-
verter deﬁbrillator, sudden cardiac deaths.
Introduction
The implantable cardioverter deﬁbrillator (ICD) is the
most effective way to prevent a ventricular arrhythmia
from being fatal [1]. It is a life-preserving device—
without it few patients experiencing ventricular
arrhythmias arrive in hospital soon enough to survive
[2]. ICDs have been recommended for several years for
patients with prior ventricular arrhythmias (so-called
secondary prevention of sudden cardiac death [SCD])
[1,3]. Most recently, indications for ICD have been
expanding as clinical trials have shown improved sur-
vival in patients with serious heart disease who have
not yet suffered a ventricular arrhythmia (so-called pri-
mary prevention of SCD) [4]. The direct economic
consequences of this expansion can be considerable,
however. For example, the results of the Sudden Car-
diac Death in Heart Failure Trial (SCD-HeFT) led to
the expansion of coverage in the United States, and it
is expected that Medicare beneﬁciaries eligible for an
ICD will increase by one-third, to nearly 500,000—an
additional 25,000 patients will be implanted in the
ﬁrst year of coverage, and potentially up to 2500 lives
will be prolonged [5].
Even before primary prevention was being consid-
ered, there was already evidence that ICDs have not
been uniformly adopted, and that this is probably due
to economic, as well as clinical, concerns [1,6]. Various
cost-effectiveness analyses of ICD use have been com-
pleted [7–10] and have generally concluded that the
cost-effectiveness of ICD use is borderline, except
when patients are at high risk of SCD. This conclusion
is largely due to the methods selected for the analyses:
Cost-effectiveness studies use duration of life, often
adjusted to reﬂect the average quality of life, as the
measure of beneﬁt. This leads, in our opinion and that
of others [11], to undervaluing of the beneﬁt when the
intervention tends to be for more elderly patients, espe-
cially if they are chronically ill and thus likely to have
their survival “quality-adjusted” downward. Although
cost-effectiveness analyses are prevalent in health tech-
nology assessments, the morality of valuing a person’s
life less because they are older or ill is questionable. In
this article, we provide a different view of the eco-
nomic desirability of ICD use for primary prevention
of SCD by carrying out a cost-beneﬁt assessment com-
pared with amiodarone in the UK and France. This
Caro et al.14
method was chosen because it places an equal value on
each life saved.
Methods
Data and Sources
Because no single data source provided all of the
required age-dependent arrhythmia and mortality
inputs, these were derived by combining data from two
sources. The major source for inputs was the published
results of the SCD-HeFT [4]—individual patient data
were not made available to us. The SCD-HeFT was a
randomized, controlled, primary prevention trial of
2521 patients with mild to moderate heart failure (New
York Heart Association class II/III) and ejection frac-
tions of 35% or less. All the patients were receiving op-
timal medical therapy before enrollment (beta-blocker,
diuretic, statin, and ACE inhibitor). Patients were
assigned to ICD (N = 829), amiodarone (N = 845), and
placebo (N = 847); median follow-up was 3.8 years.
The 5-year mortality in the placebo group was 36.1%.
When amiodarone was compared with placebo, there
was no signiﬁcant difference, whereas those receiving
an ICD had a 23% reduction in mortality, an absolute
decrease of 7.2% after 5 years. Other information
obtained from the trial was the initial age distribution
and all-cause mortality over 5 years.
The second major source—for mortality rates in
ﬁve age groups and the probability of developing
severe amiodarone toxicity—was a published meta-
analysis of trials of amiodarone based on individual
patient data [12,13]. Thirteen trials (N = 6252) were
included in the meta-analysis, which evaluated the
effect of prophylactic amiodarone on all-cause death
and fatal arrhythmia after myocardial infarction or
congestive heart failure (22%). The mean follow-up
was 1.4 years.
Model
A discrete event simulation was designed to follow a
patient’s course after implantation with an ICD or ini-
tiation of amiodarone for primary prevention of SCD
(Fig. 1). Individual patients were created by assigning
unique characteristics to each one: For example, each
patient was assigned an age based on the SCD-HeFT
population [4], which had a median age of 60.1 years
(25th percentile 51.7 years, 75th percentile 68.5
years). Then each patient was “cloned” to ensure com-
parison of identical cohorts. One clone received an
ICD, the other amiodarone, and both also received
optimal medical therapy (beta-blocker, diuretic, statin,
and ACE inhibitor). The rate of life-threatening
arrhythmia was the same for the clones. If a severe
arrhythmia occurred, the model determined whether
the patient survived the event and then whether a hos-
pitalization occurred, and these consequences differed
depending on which treatment the patient was on: The
probabilities were lower with an ICD. Survivors of an
event were exposed to a higher rate of life-threatening
arrhythmia for the following 6 months. Each patient
with an ICD may develop postimplantation complica-
tions (lead- and device-related), which may lead to
hospitalization for a reoperation or revision. Patients
on amiodarone may develop severe drug toxicity. A
patient with amiodarone toxicity was assumed to be
hospitalized and a probability of death was assigned.
The age-dependent hazard of death from causes other
than severe arrhythmia was the same for each of the
treatments. When a patient died or reached the end of
Figure 1 Schematic representation of model
implemented as a discrete event simulation.
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the time horizon (5 years), he or she was removed from
the simulation. During the simulation, the number of
deaths, revisions, and hospitalizations were counted,
and their associated direct medical costs (given the
health-care system perspective) were accrued accord-
ing to the patient’s assigned treatment. The simulation
was carried out using ARENA v8.01 (Rockwell Soft-
ware, Inc., Warrendale, PA) [14].
The simulation was controlled by two equations:
the severe arrhythmia rate and other-cause mortality as
functions of age; and two age-independent parameters:
the case-fatality rates of a severe arrhythmia by treat-
ment (Table 1). The equation for life-threatening
arrhythmia was derived by combining SCD-HeFT
results with the age-speciﬁc fatality data from the
meta-analysis of amiodarone trials. The SCD-HeFT
has not reported the arrhythmia-related deaths sepa-
rately but indicated that “appropriate ICD shocks”
were reported at an average hazard of 5.1% per year.
The average hazard of dying from an arrhythmia in the
trial was derived for amiodarone users by assuming
that 90% [15–17] of the 5.1% would be fatal. This
average estimate was translated to age-conditional
hazards (hage) by calibrating the equation derived from
the amiodarone meta-analysis: hage = 2.0299E−4 × Age
+ 4.7318E−5, (R2 = 0.98). The calibration involved
changing the intercept so that the derived hazard
matched the average one from the trial at the median
age of 61 years. Age-speciﬁc values of the death hazard
were then derived, and the implied severe arrhythmia
rates were estimated using the 90% case-fatality rate.
The  resulting  severe  arrhythmia  hazard  (SARRage)
for each 3-month period was therefore SARRage =
2.2555E−4 × Age − 1.91062E−3, where Age is the cur-
rent age. Survivors of a severe arrhythmia are, by def-
inition, in a secondary prevention context. They are
assigned a higher arrhythmia hazard (1.5-fold) for the
following 6 months.
Because the SCD-HeFT trial reported the effect of
an ICD on all-cause mortality only, the case-fatality
rate with arrhythmia had to be derived. This was car-
ried out by assuming that the entire reduction seen in
the trial was due to prevention of arrhythmia deaths
(i.e., no reason to assume ICD avoids deaths due to
other causes). Thus, an estimate of the hazard of
deaths due to other causes was needed, and this was
obtained by subtracting from the all-cause death haz-
ard of 8.9 per 100 person-years for amiodarone, the
arrhythmia death hazard: 8.9 − (5.1 × 0.9) = 4.31 per
100 person-years. For patients with an ICD, the
arrhythmia death hazard can now be obtained by sub-
tracting this common other death hazard from the
observed overall mortality of 6.8 per 100 person-years:
6.8 − 4.31 = 2.49 per 100 person-years. This yields
an estimate for the ICD case-fatality rate of 49%
(2.49/5.1).
Because all-cause mortality increases with age but
the proportion of deaths due to arrhythmia decreases
[12], the rate of deaths due to other causes also
increases with age. The age-speciﬁc other-cause mor-
tality was derived by subtracting the age-speciﬁc
arrhythmia mortality from the corresponding all-cause
mortality. The latter was obtained by applying an age-
speciﬁc cause ratio to the age-speciﬁc arrhythmia mor-
tality. The cause ratio, CRage, was estimated using the
linear ﬁt of the observed ratios of arrhythmia to the
all-cause mortality reported in the meta-analysis of
amiodarone trials [12]: CRage = −9.0139E−3 × Age +
0.96165 (R2 = 0.9). The ratio equation was calibrated
to SCD-HeFT by changing the intercept to 1.1016 to
match the ratio calculated from the all-cause mortality
observed in the trial and the derived arrhythmia-
related mortality for the age of 61 years. The age-
dependent all-cause mortality was then derived using
the age-speciﬁc ratio given by this equation and the
age-speciﬁc arrhythmia mortality derived for each of
Table 1 Source and derivation (given in {}) of main model inputs (in italics) relating to mortality and arrhythmia rates
Input Source Amiodarone ICD
Severe arrhythmia rate (SARR)
Mean SCD-HeFT Same as ICD 5.1%
Age-dependent Meta-analysis* 2.2555 E−4 Age − 1.91062 E−3
Case-fatality rate (CFR) [15–17], derived 90% 49% {ARM/SARR}
All-cause mortality (ACM)
Mean SCD-HeFT 0.089 0.068
Age-dependent Meta-analysis Age-dependent ARM/CR
Arrhythmia mortality (ARM)
Mean Derived 0.0459 {SARR × CFR} 0.0249 {ACM − OCM}
Age-dependent Meta-analysis Age-dependent SARR × CFR
Age-dependent cause ratio (CR)
Mean SCD-HeFT 51.57% {ARM/ACM} 36.62% {ARM/ACM}
Age-dependent Meta-analysis* − 9.0139 E−3 × Age + 1.1016
Other-cause mortality (OCM)
Mean Derived 0.0431 {ACM − ARM} Same as amiodarone
Age-dependent Derived Age-dependent ACM − ARM
*Calibrated to the SCD-HeFT mean.
ICD, implantable cardioverter deﬁbrillator; SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial.
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the simulated amiodarone users. The resulting age-
dependent functions are illustrated in Figure 2.
Adverse Events
In the SCD-HeFT, all devices were inserted as an out-
patient procedure, and ICD-related complications
were experienced by 5% of the patients at the time of
the implantation. Outpatient insertion of the ICD is
not currently routine practice, however, so in the sim-
ulation all patients were admitted to hospital for the
procedure. Thus, complications arising during the
implant procedure do not change the cost of the hos-
pital stay. Annual lead and device complication risks,
0.9% and 0.2%, respectively, were estimated from
data provided by Medtronic [18], which are consistent
with recent reports [19]. When a complication arises,
half are assumed to lead to reoperation and the rest to
a revision procedure. The risk of pulmonary toxicity
with amiodarone (1% per year) was obtained from a
published meta-analysis [13]. The probability of dying
from pulmonary toxicity was set at 10% [20].
Value of a Life
Each life “saved” was assigned a monetary value devel-
oped by government authorities using the willingness-
to-pay (WTP) approach. In the simplest form of this,
the subject is asked how much he or she is willing to
pay to obtain a given reduction in the risk of death.
Because this direct approach is subject to many biases
and measurement problems, more sophisticated meth-
ods have been developed to elicit WTP [21]. These
establish the value of intangibles such as a “life” by
creating an imaginary market and asking representa-
tives of the society to carry out hypothetical trades in
that market [22]. Those contingency trades are then
taken to reveal the value of the intangible at issue.
The monetary value of a prevented fatality recom-
mended by the UK government for cost-beneﬁt
analyses of scenarios involving accidental and near
immediate loss of life was based on research conducted
by the Department of Transport [23]. Since 1993, the
UK Department of Transport has based their valua-
tion of preventing road trafﬁc fatalities on a WTP
approach, and their estimate has been reviewed in the
contexts of rail transport, domestic ﬁres and public
ﬁres, and similar values elicited [24]. The monetary
value  of  a  life  used  for  the  UK  analyses  was  from
a recent Department of Transport report [24]
(£1,312,260, 2003 GBP) inﬂated to 2004
(£1,445,000, €2.1 million) [25]. The French govern-
ment commissioned a study that recommended trans-
port investment decisions be made using a value of
€2.0 million (2000) [26]. Consistent with the princi-
ples of cost-beneﬁt analysis, the value of a life was not
adjusted to take into account the age of the beneﬁci-
aries nor their illness [24].
Costs
Details of the cost inputs and sources are provided in
Table 2 [27–34]. Costs are reported in 2004 Euros.
These include hospitalization, ICD, and medication
costs. Where necessary, the costs were inﬂated using
the appropriate price index to 2004 [26]. Each patient
in the ICD cohort accrues an initial hospitalization and
ICD cost (including the lead and device costs). All
postoperative complications were assumed to lead to a
revision and accrue a cost. When a reoperation was
required, then both the revision and replacement
device costs were assigned.
For patients on amiodarone, there is an initial cost
when therapy is started, and the daily cost of treat-
ment. When severe amiodarone toxicity occurs, the
patient accrues a hospital cost. Optimal medication
costs were assigned to each patient in addition to the
ICD or amiodarone costs. The probability of hospital-
ization after a severe arrhythmia was estimated
(Table 3). Without the ICD, these arrhythmias are
almost always fatal so it was assumed that 100% of
the survivors on amiodarone are hospitalized. Most
patients with an ICD who receive an “appropriate
shock” and survive the arrhythmic event do not need
to be hospitalized (Medtronic, pers. comm.). No cost
was assigned to a death from other causes.
Analyses
Lives prolonged and the associated monetary value
assigned to this beneﬁt were estimated over 5 years.
The direct medical costs of ICD implantation, compli-
cations (revision, reoperation), amiodarone treatment,
hospitalization to manage toxicity, and optimal medi-
cation (beta-blocker, diuretic, or ACE inhibitor) were
also estimated. Beneﬁts and costs were discounted at
3.5% for the UK and 3% for France [35,36]. At the
end of the simulation, the monetary value of the health
beneﬁt was applied and the cost-beneﬁt ratio was cal-
culated as the net direct cost of ICD versus amiodarone
Figure 2 Age-speciﬁc risks derived using data from the Sudden Cardiac
Death in Heart Failure Trial and the meta-analysis.
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treatment divided by the monetary value of the
number of lives saved. The ratio and the net difference
between the value of the health beneﬁt and the invest-
ment required were derived. The ratio represents the
amount invested to obtain one monetary unit of ben-
eﬁt; if it is less than one it indicates a good result
because it implies that the value of the beneﬁts exceeds
the net direct costs.
Sensitivity analyses were conducted on all key
parameters, including age, case-fatality rates, arrhyth-
mia rates, and the probability of hospitalization.
Uncertainty in the base case estimates was examined
using 100 model replications. Each replication
simulated the experience of 1000 patients with each
treatment.
Validation. Technical veriﬁcation of the model was
assessed by extensive extreme value analyses, internal
testing, and “debugging,” and by a careful review of
the model calculations by a modeler not involved in
the initial programming. Face validity was assessed by
presentation of the model to clinical experts. The con-
sistency of the model’s predictions against the SCD-
HeFT results was veriﬁed. The SCD-HeFT reported a
5-year mortality in the placebo group (36.1%), it was
not signiﬁcantly different for amiodarone, and a sig-
niﬁcantly lower risk (hazard ratio [HR] 0.77) for the
ICD treatment group. The model predicts 36.9% 5-
year mortality without the ICD, and 29.6% with the
ICD (HR 0.76).
Results
The model predicts that 37.0% of the patients receiv-
ing amiodarone will die within 5 years of the start of
treatment, compared with 29.7% of those who receive
an ICD, a relative reduction of 19.7% and an absolute
decrease of 7.3%. Thus, ICD use in 1000 patients is
predicted to prevent 73 premature deaths over 5 years.
The resulting net additional direct medical cost over
5 years for implanting an ICD in the 1000 patients
compared with using amiodarone alone was €26,222
per patient in the UK and €20,008 in France (Table 4).
Table 2 Direct medical cost inputs (in 2004 Euros)
Item Unit UK France
Implantable cardioverter deﬁbrillator
Lead and device* 23,575 15,500
Hospital stay Initial implant 7,184 4,984
Revision 5,192 4,580
Amiodarone
Initiation of treatment† 4,294 75
Hospital stay‡ Severe toxicity 252 2,942
Medication§ Per Diem 0.33 0.37
Optimal medication|| Per Diem
Beta-blocker 0.03 0.21
Diuretic 0.06 0.07
Statin 1.20 1.06
ACE inhibitor 0.32 0.65
Severe arrhythmia Hospital stay 7,184 4,984
Cost estimates were derived from the following sources:
*ICD (Medtronic, pers. comm.).
†Amiodarone initiation presumed to be during a hospital stay in the UK [27], and at an outpatient visit with appropriate procedures in France [28].
‡Hospital stay for severe toxicity in the UK [27], France [29,30].
§Amiodarone UK [31], France [32].
||Optimal medications UK [33], France beta-blocker [34], diuretic [32], statin [32], ACE inhibitor [34].
Table 3 Model inputs
Parameter ICD Amiodarone
Severe arrhythmia
Annual risk, range (%)* 3.3–6.9 3.3–6.9
Hospitalization
Survivors (%) 5 100
Fatal (%) 17 17
Death from other causes
Annual risk, range (%)* 1.3–12.3 1.3–12.3
Adverse events
Annual risk (%) Lead—0.9 Toxicity—1
Device—0.2
*Age-dependent estimates.
ICD, implantable cardioverter deﬁbrillator.
Table 4 Cost-beneﬁt assessments over 5 years for the UK and
France for 1000 patients (discounted at 3.5% for the UK and 3%
for France)
Parameter UK France
Cost*
ICD 33.5 million (262,808) 23.7 million (363,070)
Amiodarone 7.3 million (66,799) 3.7 million (316,350)
Net 26.2 million 20.0 million
Value of lives saved† 153.1 million 135.5 million
Cost-beneﬁt ratio‡ 0.17 0.14
*Cumulative costs in Euros (€) over 5 years for 1000 patients. Results are the mean
(SD) of 100 replications.
†ICD use was predicted to prevent 73 premature deaths over 5 years for 1000
patients. Value of lives saved = Number of lives saved  × Monetary value assigned to
a life.
‡Cost-beneﬁt ratio = Net costs/Value of lives saved.
ICD, implantable cardioverter deﬁbrillator.
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According to the value currently assigned to a life in
each country, the beneﬁt of preventing 73 deaths is val-
ued at €153 million in the UK and at €135.5 million in
France. Comparing this with the additional direct
medical costs yields a cost-beneﬁt ratio of 0.17 for the
UK and of 0.14 for France. In other words, the health
beneﬁt gained is more than ﬁve times as valuable to
these societies as the net amount that has to be
invested. The net beneﬁt (value of lives saved − net
cost) was valued at €127 million in the UK and €115
million in France.
The monetary value assigned to a life is a key input
in this simulation and so changes in this parameter
affect the results considerably. Therefore, in the sensi-
tivity analysis, the relation of the cost-beneﬁt ratio to
monetary values assigned to a life was examined
(Figs. 3 and 4). The breakeven point (i.e., the value of
a life at which the beneﬁts just equal the net costs) was
found to be €359,210 for the UK and €274,083 for
France. Thus, ICD treatment is a very worthwhile
investment as long as these societies assign a value to a
life that is above these thresholds. Other sensitivity
analyses are reported in Table 5. Varying these other
parameters did not have a major impact on the ratios
predicted. Another key input in the simulation is the
rate of arrhythmia, and hence the risk of a sudden car-
diac death. The arrhythmia rates are lower for younger
patients, so the ratio is slightly less favorable in this age
Figure 3 Cost-beneﬁt ratio versus value of life in the UK (base case sym-
bol ) and France (base case symbol H17009).
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Table 5 Univariate sensitivity analysis
Parameter Value
Total deaths Cost-beneﬁt ratio 
Amiodarone ICD NET UK France
Base case 370 297 73 0.17 0.14
Age group
40–50 234 167 67 0.19 0.15
50–60 314 237 77 0.17 0.13
60–70 416 340 76 0.16 0.13
70–80 538 467 71 0.17 0.14
Case-fatality rate
Amiodarone 80% 372 299 73 0.17 0.14
ICD 39%
Amiodarone 95% 369 297 72 0.17 0.14
ICD 54%
Hospitalization rates
Amiodarone Survive 80% 369 297 72 0.18 0.14
Fatal 10%
Survive 90% 368 300 68 0.18 0.15
Fatal 25%
ICD Survive 0% 367 296 71 0.18 0.14
Fatal 10%
Survive 10% 369 298 71 0.18 0.14
Fatal 25%
Severe arrhythmia rate
3%* 379 313 66 0.19 0.16
8%* 363 286 78 0.16 0.12
*Age-dependent estimates applied, assuming these values for patients aged 61 years.
ICD, implantable cardioverter deﬁbrillator.
Figure 4 Net beneﬁt (value of lives saved − net cost) versus value of life
in the UK (base case symbol ) and France (base case symbol H17009).
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group because fewer patients beneﬁt from the ICD. In
this simulation the risk of death from other causes
besides arrhythmia is assumed to increase, and so
slightly less favorable results are observed for patients
more than 70 years old.
Discussion and Conclusion
This cost-beneﬁt study estimates that policies allowing
ICDs to be implanted for primary prevention of SCDs
in patients with heart failure will lead to an additional
direct medical cost of between €20,000 and 26,000 per
patient but will prolong 73 lives per 1000 implants.
From an economic viewpoint, it is expected that
investment in ICD will be considered worthwhile
whenever a society values a life at more than about
€274,000. This is a level of investment that is well
below what has been judged acceptable for other life-
saving interventions, such as vaccination programs,
and also for regulatory policies adopted for injury pre-
vention, such as rear-seat belts, air bags, or decreasing
environmental pollution [37–40], although in the
United States somewhat different criteria have been
applied in different sectors of American society, with
lower levels of investment often expected for medical
interventions [41].
Several cost-effectiveness analyses of ICD for pri-
mary prevention of SCD have been published as each
additional clinical trial was completed [7–10]—where
the value of saving lives is expressed in terms of
expected gains in either length or quality of life. For
example, recently Sanders et al. [8] developed a
Markov model incorporating the efﬁcacy of ICD as the
relative risk of death based on each of the hazard ratios
reported in six primary prevention trials—the Multi-
center Automatic Deﬁbrillator Implantation Trial
(MADIT)-I, MADIT-II, the Multicenter Unsustained
Tachycardia Trial, the Deﬁbrillators in Non-ischemic
Cardiomyopathy Treatment Evaluation trial, the Com-
parison of Medical Therapy, Pacing, and Deﬁbrillation
in Heart Failure trial, and the SCD-HeFT. Over a life-
time use of an ICD was predicted to add between 1.01
and 2.99 quality-adjusted life-years (QALYs), with net
costs between $68,300 and $101,500, and the cost-
effectiveness estimates of the ICD compared with con-
trol therapy ranged widely from $34,000 to $70,200
per QALY gained.
As the beneﬁt in a cost-effectiveness study is deﬁned
in terms of the expected longevity as well as quality of
life, lifesaving treatment among older or sicker indi-
viduals will lead to less favorable QALY gains and
higher cost-effectiveness ratios than for younger or
healthier patients [11,42]. Those analyses are assum-
ing a particular utilitarian framework, where the goal
is to maximize QALYs within a society, and in the
health sector this approach has been found to work
well to assess treatments that relieve pain or disability
but perhaps should not be the only approach when the
treatment prevents premature deaths. The utilitarian
approach of cost-effectiveness analyses ignores the eth-
ical and equity issues that arise when lifesaving inter-
ventions are not extended to particular groups on the
basis that they are mostly older or sick patients.
Although there may be a sense that allocation of scarce
resources should be preferential toward younger or
healthier people, there are equally compelling argu-
ments that fairness (especially in the context of tax-
payer supported health care) dictates that the system
should allocate based on need. Products such as ICDs
are a particularly difﬁcult problem for health-care
decision-makers responsible for allocating resources,
because denial of access to this care conﬂicts with the
widely accepted “rule of rescue,” that is the imperative
we all feel to try to save the life of an identiﬁed person
[43,44]. For example, when the Oregon Health Serv-
ices Commission tried to prioritize health-care services
based on cost per QALYs, public outcry led to lifesav-
ing treatments being placed in a special high-priority
category with no link to their cost-effectiveness [45].
Hadorn [44] felt that the experience in Oregon
reﬂected a fundamental conﬂict between results of
cost-effectiveness analyses and the powerful human
impulse to save a life. In any case, there is little evi-
dence that the inequity that results from the use of the
QALY correctly reﬂects any discrimination the society
wishes to incorporate in its decision-making.
The cost-beneﬁt approach was used instead of the
more common cost-effectiveness analysis because it
was felt to be a preferable alternative way to assess the
value of a lifesaving intervention such as the ICD,
which is designed to preserve a life when a severe
arrhythmia occurs but has no other day-to-day health
beneﬁt—in this it is like a seat belt, a helmet, and so
on. The approach adopted here does not discriminate
by assigning a lower value to the lives of older people
(who have a lower life expectancy and, thus, less life-
years to be gained) or of those who are irreversibly ill
with heart failure (and, thus, gain less QALYs because
their quality is already compromised permanently).
Although medical practice may triage care toward
younger individuals (e.g., in the UK children are
assigned priority for receiving a renal transplant) [46],
the morality of age-based rationing has been a matter
of some debate [42,45,47,48], and not everyone agrees
with the premise that society should place a lower
value on the lives of the elderly or the ill. For example,
Johri et al. [48] reported that for a lifesaving scenario,
although 57% preferred allocating resources to a pro-
gram serving 35-year-olds, more than a third disagreed
with this concept (38% were age-neutral, and 4% of
respondents preferred allocating resources to the pro-
gram serving the elderly). Because the adjustments
involved in estimating QALYs, or life-years gained, are
discriminatory, especially in the context of this type of
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intervention, our study contributes to the discussions
by providing a different viewpoint to that already
given by the cost-effectiveness studies. Moreover, in
cost-beneﬁt assessments the resource use and the
health gains are valued in monetary units, and so both
the investment and the return are measured on the
same scale. This can be a particularly helpful approach
because it avoids the awkward and unresolved
problem of deciding how much money per QALY is
acceptable.
Cost-beneﬁt analysis has often been used to
improve decision-making in many aspects of govern-
ment spending on lifesaving interventions other than
health care. Although to some people the monetary
valuation of human life may appear immoral, in the
UK, there is a policy requiring consideration of the
costs  and  beneﬁts  of  government  proposals  [49].
The Department of Transport value of preventing a
fatality has been used in cost-beneﬁt studies conducted
by the Home Ofﬁce, Health and Safety Executive,
Environment Agency, Food Standards Agency, and
other UK government departments [23]. In none of
these situations was consideration given to the age or
health status of the individuals affected. The values of
a life for both France and the UK were about €2
million, somewhat higher than the €1 million (range
€0.65–€2.5 million, 2000) used in Europe for cost-
beneﬁt analyses of environmental policies [50], but
consistent with recent studies in Italy and Spain
[51,52]; higher values have also been estimated [54–
57]. The threshold value estimated in these analyses is
well below all of these, however, indicating that
regardless of which estimate is used, the cost-beneﬁt
ratio for ICD use is favorable. This holds even if one
were to adjust downward the value of these patients’
lives to reﬂect their age and illness.
If a severe arrhythmia arises, death is frequently so
quick [2] that the majority are not hospitalized. Fewer
patients with an ICD will need to be hospitalized
(10%); however, the impact on the total direct medical
cost is small because the severe arrhythmia rates are
relatively low (ICDs ﬁred at about 5% per year in the
SCD-HeFT), and consequently not many hospitaliza-
tions are avoided. The largest component of the 5-year
cost estimate is the ICD and hospitalization for
implantation, which was estimated at 90% of the 5-
year costs in each country. In the SCD-HeFT, all
devices were inserted as an outpatient procedure, but
because this is not yet routine practice, in the simula-
tion all were assumed to be admitted to hospital. Each
ICD implanted in the SCD-HeFT was a single-chamber
device programmed with a simple pre-established pro-
gramming for shock therapy (detection rate for tach-
yarrhythmias of 187 beats per minute or more), and no
rate responsive pacing was allowed. Some ICDs have
additional features, e.g., biventricular pacing, but the
potential impact of these additional features on costs
and outcomes has not been established. Such informa-
tion could be of interest, because improvements in
heart failure symptoms and reductions in hospitaliza-
tions can be achieved using cardiac-resynchronization
therapy, which when combined with an ICD signiﬁ-
cantly reduces mortality [57].
A key assumption of this model is that the death
rates derived from combining data from the SCD-
HeFT and the meta-analysis of amiodarone trials are
appropriate. Published data from the SCD-HeFT were
used and a series of assumptions was made to derive
the severe arrhythmia rate and the fatality rate with an
ICD. The relationship between death risks and age was
developed from a meta-analysis of amiodarone trials
and assumed to apply to the candidates for ICD. This
assumption is reasonable for a simulation because it is
calibrated to reﬂect the death rate observed in the
SCD-HeFT, and the results are consistent with the
SCD-HeFT published results.
The use of ICD rather than amiodarone to manage
severe arrhythmic events can be anticipated to prolong
lives. Although cost-beneﬁt analyses can facilitate
comparison of health-care decisions, they do not
address affordability. Nevertheless, the breakeven
value of a life estimated here suggests that investment
in ICDs is worthwhile in European societies. This
supports clinical arguments for a greater investment
to provide patients access to this life-prolonging
treatment.
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